Scarica l'app Stockscreener
5.59
3.45%
-0.20
Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie
LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions - Yahoo Finance
Piper Sandler Maintains LENZ Therapeutics(LENZ.US) With Hold Rating, Maintains Target Price $12 - Moomoo
H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $38 - Moomoo
LENZ Therapeutics Launches VIZZ Telehealth Prescribing Option for the Treatment of Presbyopia - VisionMonday.com
H.C. Wainwright reiterates Buy on LENZ Therapeutics stock on telehealth launch - Investing.com
LENZ Reiterates by HC Wainwright & Co. -- Price Target Maintained at $38 - GuruFocus
LENZ Therapeutics Inc (LENZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LENZ Therapeutics, Inc. Launches New Telehealth Prescribing Option for VIZZ for the Treatment of Presbyopia - marketscreener.com
William Blair Maintains LENZ Therapeutics(LENZ.US) With Buy Rating - Moomoo
LENZ Therapeutics Launches Telehealth Access for VIZZ Alongside National TV Campaign - Quiver Quantitative
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ - LENZ Therapeutics
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia - Yahoo Finance
LENZLENZ Therapeutics Inc Options - Finviz
Director departure and audit committee change at LENZ Therapeutics (NASDAQ: LENZ) - Stock Titan
Price to book forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
Price to sales forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
Enterprise value to EBIT forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
Enterprise value to revenue forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
Price to earnings forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
Enterprise value to EBITDA forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ - TradingView
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to Russell Microcap Value Benchmark Index - marketscreener.com
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) added to Russell 2000 Value Benchmark - marketscreener.com
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) dropped from Russell 3000 Growth Benchmark - marketscreener.com
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) dropped from Russell 3000E Growth Benchmark - marketscreener.com
LENZ Therapeutics Surges 5.6%: Key Levels to WatchMomentum Stock Picks - dars.gov.et
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Millennium Group reports 1.60M-share (5.1%) LENZ stake (LENZ) - Stock Titan
LENZ Therapeutics, Inc. Actuals & Estimates (NASDAQ:LENZ) - TradingView
LENZ Therapeutics, Arrotex Ink Commercialization Deal for VIZZ in Australia and New Zealand - VisionMonday.com
US prices for new drugs fell in 2025 as fewer costly gene therapies were launched - marketscreener.com
LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst - Sahm
LENZ Therapeutics (LENZ) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ By Investing.com - Investing.com South Africa
LENZ Therapeutics signs exclusive VIZZ deal for Australia and New Zealand - grafa.com
LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ - Investing.com Australia
Lenz TherapeuticsArrotex Obtains Exclusive - Moomoo
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand - LENZ Therapeutics
LENZ Therapeutics, Inc. and Arrotex Pharmaceuticals Pty Ltd. Announce Exclusive License and Commercialization Agreement for VIZZ in Australia and New Zealand - marketscreener.com
LENZ Therapeutics Inc (LENZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LENZ Therapeutics, Inc. (LENZ) reports Q1 loss, beats revenue estimates - MSN
LENZ Therapeutics Inc (LENZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LENZ Therapeutics Inc (LENZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LENZ Therapeutics Inc (LENZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LENZ Therapeutics Inc (LENZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LENZ Therapeutics Inc (LENZ) Institutional Confidence - TradingKey
LENZ Therapeutics Inc (LENZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
LENZ Therapeutics Inc (LENZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RA Capital-linked entities receive 22,100 LENZ (LENZ) options via director grant - Stock Titan
LENZ (LENZ) director receives 22,100 stock options at $6.63 strike price - Stock Titan
Director awarded 22,100 LENZ Therapeutics (LENZ) stock options - Stock Titan
Director-linked entities at LENZ Therapeutics (LENZ) granted 22,100 stock options - Stock Titan
LENZ Therapeutics Shareholders Back Board and Auditor Slate - The Globe and Mail
Lenz Therapeutics shareholders elect directors and ratify auditor at annual meeting By Investing.com - Investing.com South Africa
Lenz Therapeutics shareholders elect directors and ratify auditor at annual meeting - Investing.com Australia
[8-K] LENZ Therapeutics, Inc. Reports Material Event - Stock Titan
CCCC News | C4 THERAPEUTICS INC (NASDAQ:CCCC) - ChartMill
LENZ Technical Analysis & Stock Price Forecast - Intellectia AI
Everest medicines acquires greater china rights to aceclidine presbyopia eye drop (VIZZ) - Ophthalmology Times
Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ) - Ophthalmology Times
LENZ Therapeutics adds China partner for presbyopia drug VIZZ - Yahoo Finance
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):